|
MYST3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.72189995595318E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.83680000046083E-07 |
| Normal-vs-Stage2 |
1.021840E-04 |
| Normal-vs-Stage3 |
1.07239994662223E-09 |
| Normal-vs-Stage4 |
4.20710000170743E-08 |
| Stage1-vs-Stage2 |
9.255800E-01 |
| Stage1-vs-Stage3 |
7.893800E-02 |
| Stage1-vs-Stage4 |
7.379900E-02 |
| Stage2-vs-Stage3 |
2.484600E-01 |
| Stage2-vs-Stage4 |
2.303000E-01 |
| Stage3-vs-Stage4 |
8.194600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.97870003399481E-09 |
| Normal-vs-AfricanAmerican |
6.323600E-03 |
| Normal-vs-Asian |
3.16889999996128E-06 |
| Caucasian-vs-AfricanAmerican |
3.911600E-01 |
| Caucasian-vs-Asian |
8.040000E-01 |
| AfricanAmerican-vs-Asian |
3.414200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.44320000394771E-10 |
| Normal-vs-Female |
5.91509999869899E-08 |
| Male-vs-Female |
6.772000E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.74879999995203E-06 |
| Normal-vs-Age(41-60Yrs) |
1.22990000406276E-08 |
| Normal-vs-Age(61-80Yrs) |
4.14449996544164E-09 |
| Normal-vs-Age(81-100Yrs) |
1.238970E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.781820E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.671700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.245600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.240000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.192200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.311800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.478400E-02 |
| Classical-VS-Follicular |
3.698000E-02 |
| Classical-VS-Other |
1.455040E-01 |
| Classical-VS-Normal |
5.40679999994076E-07 |
| Tall-VS-Follicular |
4.922600E-01 |
| Tall-VS-Other |
6.602600E-01 |
| Tall-VS-Normal |
3.85460000029703E-07 |
| Follicular-VS-Other |
4.658600E-01 |
| Follicular-VS-Normal |
5.20180000185277E-08 |
| Other-VS-Normal |
1.695580E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.92079996352845E-09 |
| Normal-vs-N1 |
3.8737999996652E-07 |
| N0-vs-N1 |
6.440000E-01 |
|
|
